Related Experiment Video

Updated: Mar 27, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K

Sevabertinib: First Approval

Susan J Keam1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand. dru@adis.com.

Drugs
|March 26, 2026
PubMed

Insights

Sevabertinib is a new targeted therapy for non-small cell lung cancer (NSCLC) with specific HER2 mutations. It received accelerated approval in the USA for adults with advanced NSCLC after prior treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sevabertinib is an oral, reversible small molecule tyrosine kinase inhibitor (TKI).
  • It targets human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR).
  • Developed by Bayer, it stems from a research alliance with the Broad Institute.

Purpose of the Study:

  • To summarize the development milestones of sevabertinib.
  • To highlight its first approval for treating specific non-small cell lung cancer (NSCLC) cases.

Main Methods:

  • Review of development history and regulatory submissions for sevabertinib.
  • Analysis of its mechanism of action as a HER2/EGFR inhibitor.

Main Results:

  • Sevabertinib received accelerated approval in the USA in November 2025.
  • Approval is for adults with locally advanced or metastatic non-squamous NSCLC.
  • Treatment is indicated for tumors with HER2 (ERBB2) TK domain activating mutations and prior systemic therapy.

Conclusions:

  • Sevabertinib represents a significant advancement in targeted therapy for NSCLC.
  • Its approval addresses a critical unmet need for patients with HER2-mutated NSCLC.
  • This milestone facilitates personalized treatment strategies in oncology.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
324
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
740
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K